Lantern Pharma reported a net loss of $4.2 million, or $0.39 per share, for the third quarter ended September 30, 2025, and disclosed cash and marketable securities of $12.4 million.
Research and development expenses fell 22% to $2.4 million, while general and administrative costs rose 3% to $1.9 million, reflecting a shift toward clinical development and investor relations.
The company sold 356,648 shares under its at‑the‑market program, raising $1.62 million, and maintains a cash runway that extends into the third quarter of 2026, giving it time to fund ongoing trials.
Lantern also highlighted progress in its clinical pipeline, including the completion of enrollment for LP‑184 Phase 1a and ongoing expansion of the HARMONIC trial, underscoring the company’s focus on advancing its AI‑driven oncology assets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.